Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Multiple Myeloma 56Recurrence 16Neoplasms, Plasma Cell 11Lymphoma, Mantle-Cell 10Lymphoma, Non-Hodgkin 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma 8Leukemia, Myeloid, Acute 8Lymphoma, Follicular 7Lymphoma, Large B-Cell, Diffuse 5Hematologic Neoplasms 5Waldenstrom Macroglobulinemia 4Neoplasms 4Leukemia 4Carcinoma, Non-Small-Cell Lung 4Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, B-Cell, Marginal Zone 3Lung Neoplasms 3Leukemia, Lymphocytic, Chronic, B-Cell 3Sezary Syndrome 2Paraproteinemias 2Pancreatic Neoplasms 2Mycosis Fungoides 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, B-Cell 2Leukemia, Myelomonocytic, Chronic 2Immunoproliferative Disorders 2Immune System Diseases 2Hematologic Diseases 2

Interventions

Cytarabine 6Etoposide 3Daunorubicin 3Methotrexate 2Idarubicin 2Clofarabine 2valspodar 1tipifarnib 1aldesleukin 1Vorinostat 1Topotecan 1Tacrolimus 1Pravastatin 1Peripheral Blood Stem Cell Transplantation 1Mitoxantrone 1Gemtuzumab 1Cyclosporine 1Cyclophosphamide 1Calicheamicins 1Busulfan 1Bortezomib 1Azacitidine 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia, Myelomonocytic, Acute × Bortezomib × Clear all
NCT00742625 2014-09-12

Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 1/2 Completed
95 enrolled 9 charts
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡